{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:03:45Z","timestamp":1789772625265,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"DOI":"10.7759\/cureus.116509","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:56:57Z","timestamp":1789772217000},"source":"Crossref","is-referenced-by-count":0,"title":["Reduction in Rheumatoid Factor and Matrix Metalloproteinase-3 With Successful Glucocorticoid Withdrawal After Initiation of Pemafibrate in a Patient With Rheumatoid Arthritis and Hypertriglyceridemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Kimihiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01231-1","article-title":"Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors","volume":"68","author":"Korbecki J","year":"2019","unstructured":"Korbecki J, Bobi\u0144ski R, Dutka M. Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors. Inflamm Res. 2019, 68:443-58. 10.1007\/s00011-019-01231-1","journal-title":"Inflamm Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/ar300","article-title":"NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction","volume":"3","author":"Makarov SS","year":"2001","unstructured":"Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. 2001, 3:200-6. 10.1186\/ar300","journal-title":"Arthritis Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes IB","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011, 365:2205-19. 10.1056\/NEJMra1004965","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells G","year":"2009","unstructured":"Wells G, Becker JC, Teng J, et al.. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009, 68:954-60. 10.1136\/ard.2007.084459","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values","volume":"66","author":"Inoue E","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 2007, 66:407-9. 10.1136\/ard.2006.054205","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010, 69:1580-8. 10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.01.118","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, and fenofibrate suppress microglial activation through distinct PPAR\u03b1 and SIRT1-dependent pathways","volume":"524","author":"Ogawa K","year":"2020","unstructured":"Ogawa K, Yagi T, Guo T, et al.. Pemafibrate, a selective PPAR\u03b1 modulator, and fenofibrate suppress microglial activation through distinct PPAR\u03b1 and SIRT1-dependent pathways. Biochem Biophys Res Commun. 2020, 524:385-91. 10.1016\/j.bbrc.2020.01.118","journal-title":"Biochem Biophys Res Commun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.9762","article-title":"Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia-reperfusion injury in type 1 diabetes mellitus","volume":"21","author":"Li W","year":"2021","unstructured":"Li W, Xu J, Guo X, Xia X, Sun Y. Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia-reperfusion injury in type 1 diabetes mellitus. Exp Ther Med. 2021, 21:331. 10.3892\/etm.2021.9762","journal-title":"Exp Ther Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06542-8","article-title":"Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy","volume":"12","author":"Kanno K","year":"2022","unstructured":"Kanno K, Koseki M, Chang J, et al.. Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. Sci Rep. 2022, 12:2996. 10.1038\/s41598-022-06542-8","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241195","article-title":"Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor \u03b1 modular (SPPARM\u03b1), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury","volume":"15","author":"Konishi H","year":"2020","unstructured":"Konishi H, Miyauchi K, Onishi A, et al.. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor \u03b1 modular (SPPARM\u03b1), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury. PLoS One. 2020, 15:e0241195. 10.1371\/journal.pone.0241195","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74340-5","article-title":"Selective activation of PPAR\u03b1 by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation","volume":"14","author":"Shinkai Y","year":"2024","unstructured":"Shinkai Y, Sasaki K, Tamura R, et al.. Selective activation of PPAR\u03b1 by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation. Sci Rep. 2024, 14:23816. 10.1038\/s41598-024-74340-5","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2025.159686","article-title":"Hypertriglyceridemia impairs HDL functionality, promotes macrophage metabolic activation and exacerbates antigen-induced rheumatoid arthritis in mice which can be reversed by fenofibrate treatment","volume":"1870","author":"Axiotis I","year":"2025","unstructured":"Axiotis I, Kakale A, Lazaridou D, et al.. Hypertriglyceridemia impairs HDL functionality, promotes macrophage metabolic activation and exacerbates antigen-induced rheumatoid arthritis in mice which can be reversed by fenofibrate treatment. Biochim Biophys Acta Mol Cell Biol Lipids. 2025, 1870:159686. 10.1016\/j.bbalip.2025.159686","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115797","article-title":"Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR \u03b3 activity","volume":"168","author":"Singh A","year":"2026","unstructured":"Singh A, Chaudhary R, Agarwal V, Kumar A, Chaudhary D, Mishra V. Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR \u03b3 activity. Int Immunopharmacol. 2026, 168:115797. 10.1016\/j.intimp.2025.115797","journal-title":"Int Immunopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/13880209.2015.1125931","article-title":"Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats","volume":"54","author":"Wahba MG","year":"2016","unstructured":"Wahba MG, Messiha BA, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol. 2016, 54:1705-15. 10.3109\/13880209.2015.1125931","journal-title":"Pharm Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.015008","article-title":"Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis","volume":"63","author":"Okamoto H","year":"2004","unstructured":"Okamoto H, Kamatani N. Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis. 2004, 63:1002-3. 10.1136\/ard.2003.015008","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-009-0261-2","article-title":"A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis","volume":"20","author":"Goto M","year":"2010","unstructured":"Goto M. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol. 2010, 20:238-43. 10.1007\/s10165-009-0261-2","journal-title":"Mod Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2613-z","article-title":"The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study","volume":"33","author":"Shirinsky I","year":"2013","unstructured":"Shirinsky I, Polovnikova O, Kalinovskaya N, Shirinsky V. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. Rheumatol Int. 2013, 33:3045-8. 10.1007\/s00296-012-2613-z","journal-title":"Rheumatol Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/937843","article-title":"Targeting nuclear hormone receptors: PPAR\u03b1 agonists as potential disease-modifying drugs for rheumatoid arthritis","volume":"2011","author":"Shirinsky IV","year":"2011","unstructured":"Shirinsky IV, Shirinsky VS. Targeting nuclear hormone receptors: PPAR\u03b1 agonists as potential disease-modifying drugs for rheumatoid arthritis. Int J Rheumatol. 2011, 2011:937843. 10.1155\/2011\/937843","journal-title":"Int J Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/532520-reduction-in-rheumatoid-factor-and-matrix-metalloproteinase-3-with-successful-glucocorticoid-withdrawal-after-initiation-of-pemafibrate-in-a-patient-with-rheumatoid-arthritis-and-hypertriglyceridemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:56:57Z","timestamp":1789772217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/532520-reduction-in-rheumatoid-factor-and-matrix-metalloproteinase-3-with-successful-glucocorticoid-withdrawal-after-initiation-of-pemafibrate-in-a-patient-with-rheumatoid-arthritis-and-hypertriglyceridemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.116509","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}